CUSIP 45720N103 · who reports it, how much, and how much it matters to them
27 of the 720 hedge fund managers we track reported shares of Inhibrx Biosciences, Inc. (Nasdaq: INBX) on Form 13F for 30 June 2026. Between them they reported USD 408m. The largest position belongs to Perceptive Advisors, at USD 123m. The manager with the most riding on it is PFM Health Sciences, where it is 2.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Perceptive Advisors6 funds on PPLI.com | USD 123m | 1.8% |
| 2 | Viking Global Investors4 funds on PPLI.com | USD 106m | 0.3% |
| 3 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 66m | 0.2% |
| 4 | PFM Health Sciences3 funds on PPLI.com | USD 29m | 2.5% |
| 5 | Sofinnova Investments1 fund on PPLI.com | USD 29m | 1.5% |
| 6 | Millennium Management6 funds on PPLI.com | USD 14m | 0.0% |
| 7 | Renaissance Technologies13 funds on PPLI.com | USD 5.9m | 0.0% |
| 8 | Voleon Capital Management13 funds on PPLI.com | USD 5.5m | 0.1% |
| 9 | Voloridge Investment Management6 funds on PPLI.com | USD 4.6m | 0.0% |
| 10 | Western Standard2 funds on PPLI.com | USD 4.5m | 1.5% |
| 11 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 3.3m | 0.1% |
| 12 | Empyrean Capital Partners2 funds on PPLI.com | USD 2.8m | 0.1% |
| 13 | Atom Investors1 fund on PPLI.com | USD 2.8m | 0.2% |
| 14 | POINT72 Asset Management17 funds on PPLI.com | USD 2.5m | 0.0% |
| 15 | D. E. Shaw & Co.15 funds on PPLI.com | USD 2.1m | 0.0% |
| 16 | Verition Fund Management3 funds on PPLI.com | USD 1.7m | 0.0% |
| 17 | Marshall Wace LLP84 funds on PPLI.com | USD 834,000 | 0.0% |
| 18 | Brevan Howard Capital Management39 funds on PPLI.com | USD 725,000 | 0.0% |
| 19 | Squarepoint Ops7 funds on PPLI.com | USD 620,000 | 0.0% |
| 20 | Platinum Investment Management11 funds on PPLI.com | USD 582,000 | 0.1% |
| 21 | Cannon Global Investment Management2 funds on PPLI.com | USD 559,000 | 1.6% |
| 22 | Exoduspoint Capital Management7 funds on PPLI.com | USD 532,000 | 0.0% |
| 23 | Balyasny Asset Management25 funds on PPLI.com | USD 448,000 | 0.0% |
| 24 | Jain Global1 fund on PPLI.com | USD 312,000 | 0.0% |
| 25 | Fora Capital1 fund on PPLI.com | USD 301,000 | 0.0% |
| 26 | Nine Masts Capital1 fund on PPLI.com | USD 284,000 | 0.0% |
| 27 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 78,119 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | PFM Health Sciences | USD 29m | 2.5% |
| 2 | Perceptive Advisors | USD 123m | 1.8% |
| 3 | Cannon Global Investment Management | USD 559,000 | 1.6% |
| 4 | Western Standard | USD 4.5m | 1.5% |
| 5 | Sofinnova Investments | USD 29m | 1.5% |
| 6 | Viking Global Investors | USD 106m | 0.3% |
| 7 | Atom Investors | USD 2.8m | 0.2% |
| 8 | Schonfeld Strategic Advisors | USD 66m | 0.2% |
| 9 | Platinum Investment Management | USD 582,000 | 0.1% |
| 10 | Arrowmark Colorado Holdings | USD 3.3m | 0.1% |
Inhibrx Biosciences, Inc. trades under the symbol INBX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 45720N103.
27 of the 720 hedge fund managers PPLI.com tracks reported Inhibrx Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Perceptive Advisors (USD 123m), Viking Global Investors (USD 106m), Schonfeld Strategic Advisors (USD 66m), PFM Health Sciences (USD 29m) and Sofinnova Investments (USD 29m).
27 managers in our coverage reported it, and between them they run 331 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
PFM Health Sciences, where the position was 2.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Inhibrx Biosciences, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.